Article
Cystic fibrosis gene modifier SLC26A9 modulates airway response to CFTR-directed therapeutics.
Human molecular genetics - 15 Oct 2016
Strug Lisa J, Gonska Tanja, He Gengming, Keenan Katherine, Ip Wan, Boëlle Pierre-Yves, Lin Fan, Panjwani Naim, Gong Jiafen, Li Weili, Soave David, Xiao Bowei, Tullis Elizabeth, Rabin Harvey, Parkins Michael D, Price April, Zuberbuhler Peter C, Corvol Harriet, Ratjen Felix, Sun Lei, Bear Christine E, Rommens Johanna M
Abstract excerpt
Cystic fibrosis is realizing the promise of personalized medicine. Recent advances in drug development that target the causal CFTR directly result in lung function improvement, but variability in response is demanding better prediction of outcomes to improve management decisions. The genetic modifier SLC26A9 contributes to disease severity in the CF pancreas and intestine at birth and here we assess its...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.